

-17-

CLAIMS

WHAT IS CLAIMED IS:

Sub A3

1. The method of treating a patient affected with a glycolipid storage disease comprising administering to said patient both a N-alkyl derivative of deoxynojirimycin having from about two to about twenty carbon atoms in the alkyl chain and a glucocerebrosidase enzyme in an amount effective for alleviating or inhibiting said glycolipid storage disease.
2. The method of Claim 1 in which the N-alkyl derivative of deoxynojirimycin contains four to six carbon atoms in the alkyl chain.
3. The method of Claim 2 in which the N-alkyl derivative of deoxynojirimycin is N-butyl-DNJ.
4. The method of Claim 1 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ or N-decyl-DNJ.
5. The method of Claim 4 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ.
6. The method of Claim 1 in which the glycolipid storage disease is Gaucher's disease.
7. The method of Claim 3 in which the glycolipid storage disease is Gaucher's disease.
8. The method of Claim 5 in which the glycolipid storage disease is Gaucher's disease.

-18-

but as 9. The method as in any one of Claims 1-8, in which the N-alkyl derivative of deoxynojirimycin is administered in a dose of from about 0.1 to about 1000 mg and the glucocerebrosidase is administered in a dose of about 7.5 to about 60 U per kilogram of weight of said patient in a pharmaceutically acceptable diluent or carrier.

10. A combination drug composition comprising a N-alkyl derivative of deoxynojirimycin having from about two to about twenty carbon atoms in the alkyl chain and a glucocerebrosidase enzyme in a pharmaceutically acceptable diluent or carrier.

11. The composition of Claim 10 in which the N-alkyl derivative of deoxynojirimycin is N-butyl-DNJ.

12. The composition of Claim 10 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ or N-decyl-DNJ.

13. The composition of Claim 12 in which the N-alkyl derivative of deoxynojirimycin is N-nonyl-DNJ.
